Berd, David <br/><br/>
Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Feb 2004 
 - 403-15 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2004.06.043  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adjuvants, Immunologic<br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents, Alkylating--administration & dosage<br/>Cancer Vaccines--therapeutic use<br/>Combined Modality Therapy<br/>Cyclophosphamide--therapeutic use<br/>Dinitrobenzenes--immunology<br/>Female<br/>Follow-Up Studies<br/>Haptens<br/>Humans<br/>Hypersensitivity, Delayed--immunology<br/>Male<br/>Melanoma--drug therapy<br/>Middle Aged<br/>Mycobacterium bovis<br/>Neoplasm Recurrence, Local--drug therapy<br/>Skin Neoplasms--drug therapy<br/>Survival Rate